Nkarta Inc.

News & Events

Press Releases

In The Media

1. Nkarta to Participate in an April Investor Conference

   GlobeNewswire APR 1, 2025 8:01 AM EDT
   SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a bi...
   READ ARTICLE

2. Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

   GlobeNewswire MAR 26, 2025 4:01 PM EDT
   Differentiated development program includes two Nkarta clinical trials and two investigator-spons...
   READ ARTICLE

3. Nkarta to Participate in March Investor Conferences

   GlobeNewswire FEB 25, 2025 8:01 AM EST
   SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a bio...
   READ ARTICLE

4. Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

   GlobeNewswire DEC 5, 2024 6:01 AM EST
   Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis...
   READ ARTICLE

5. Nkarta to Participate in an Upcoming Investor Conference

   GlobeNewswire NOV 26, 2024 7:02 AM EST
   SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a bio...
   READ ARTICLE

6. Nkarta to Participate in an Upcoming Investor Conference

   GlobeNewswire NOV 12, 2024 8:02 AM EST
   SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a bio...
   READ ARTICLE

7. Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

   GlobeNewswire NOV 7, 2024 4:02 PM EST
   First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019...
   READ ARTICLE

8. Nkarta to Participate in Upcoming Investor Conference

   GlobeNewswire SEP 3, 2024 4:01 PM EDT
   SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a bi...
   READ ARTICLE

9. Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

   GlobeNewswire AUG 13, 2024 9:03 PM EDT
   Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune...
   READ ARTICLE

10. Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

    GlobeNewswire AUG 13, 2024 4:01 PM EDT
    Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune...
    READ ARTICLE